These tumors may secrete excessive quantities of hormone such as gastrin, insulin, vasoactive intestinal polypeptide (VIP), glucagon, or somatostatin and may be associated with distinct clinical syndromes, with approximately one third of these neoplasms becoming clinically apparent. This evidence concerns the gene GAST and neoplasm.